TAT(SZ:002433)2016-04-26 16:00Financial Performance - The company's operating revenue for Q1 2016 was CNY 635,854,926.82, representing an increase of 87.96% compared to CNY 338,299,842.10 in the same period last year[7]. - Net profit attributable to shareholders was CNY 38,197,780.11, up 10.08% from CNY 34,699,280.67 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 36,867,337.81, reflecting a 7.79% increase from CNY 34,201,447.00 in the previous year[7]. - Operating revenue increased by 297,555,084.72 CNY, a growth of 87.96%, primarily due to revenue growth from existing business and subsidiary Guangdong Kang Aido Chain Pharmacy Co., Ltd.[12]. - The net profit attributable to shareholders for the first half of 2016 is expected to be between 82.23 million and 97.18 million RMB, representing a growth of 10.00% to 30.00% compared to the same period in 2015[22]. - The net profit for the first half of 2015 was 74.76 million RMB, indicating a positive performance trend[22]. - The increase in net profit is attributed to the growth in main business revenue[22]. Assets and Shareholder Information - The total assets at the end of the reporting period were CNY 6,374,045,532.10, an increase of 8.61% from CNY 5,868,858,395.62 at the end of the previous year[7]. - The number of ordinary shareholders at the end of the reporting period was 61,884[10]. - The largest shareholder, Taian Group Co., Ltd., held 32.56% of the shares, amounting to 251,589,701 shares, with 61,949,200 shares pledged[10]. Cash Flow and Operating Activities - The net cash flow from operating activities was negative CNY 142,369,866.20, worsening by 24.60% compared to negative CNY 114,261,784.08 in the same period last year[7]. - Cash received from sales of goods and services increased by 290,677,063.59 CNY, a growth of 81.47%, reflecting higher cash inflows from increased operating revenue[21]. - Cash paid for purchasing goods and services increased by 251,522,184.63 CNY, a growth of 68.09%, due to increased procurement for health industry development and Kang Aido's pharmaceutical purchases[22]. - Cash received from investment activities decreased by 265,223,058.54 CNY, a decline of 119.16%, primarily due to less cash recovered from bank guaranteed financial products compared to the previous year[29]. - Cash received from borrowings increased by 896,000,000.00 CNY, a growth of 100.00%, due to the need for short-term loans during the reporting period[32]. - Cash paid for debt repayment increased by 320,000,000.00 CNY, a growth of 7122.22%, mainly due to the repayment of due bank loans during the reporting period[33]. Expenses - Operating costs rose by 254,925,620.46 CNY, an increase of 116.58%, mainly driven by the increase in operating revenue during the reporting period[13]. - Sales expenses increased by 25,313,989.43 CNY, a growth of 57.89%, attributed to higher sales promotion costs, marketing personnel salaries, and e-commerce platform fees[14]. - Financial expenses surged by 10,762,827.16 CNY, a dramatic increase of 418.87%, primarily due to increased interest on corporate bonds and loans[15]. - Other operating income rose by 981,504.12 CNY, a growth of 156.41%, mainly due to increased government subsidies received compared to the previous year[17]. Accounts Receivable and Current Assets - Accounts receivable increased by CNY 107,299,878.30, a rise of 43.04%, attributed to increased wholesale business from subsidiaries[14]. - Other current assets decreased by CNY 13,753,594.89, a decline of 75.55%, primarily due to a reduction in deductible taxes[14].